ICCC Q3 2023 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+12.5% YoY

Gross Profit

$1M23.5% margin

Operating Income

-$1M-21.9% margin

Net Income

-$940,000-17.4% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+52.8%

Cash Flow

Operating Cash Flow

-$507,754

Free Cash Flow

-$928,269

Stock-Based Comp.

$96,434

Balance Sheet

Total Assets

$45M

Total Liabilities

$19M

Stockholders' Equity

$26M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$5M	+12.5%
Gross Profit	$1M	$2M	-31.4%
Operating Income	-$1M	-$616,790	-92.0%
Net Income	-$940,000	-$655,078	-43.5%

Geographic Segments

UNITED STATES

$5M100%